NUMA1 and urinary bladder cancer: Other noninvasive biomarker assays have been approved in the US for the diagnosis or monitoring of bladder cancer including an Enzyme-Linked Immunosorbent Assay (ELISA) test for Nuclear Matrix Protein 22 (NMP22) (BladderChek®; Matritech Inc., Newton, MA, USA [18, 19]), a multiprobe fluorescence in situ hybridization (FISH) test (UroVysion®; Abbott Molecular, Des Plaines, IL) and an immunocytologic fluorescent assay (ImmunoCytTM/uCytTM Diagnocure; Quebec City, Quebec, Canada).